Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L. Bolton, Dean F. Bajorin, Mike Walsh et al.|Nature Genetics|2020Cited by 739
Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer ProgressionGoutam Chakraborty, Philip W. Kantoff, Joshua Armenia et al.|Clinical Cancer Research|2019Cited by 114
The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate CancerGoutam Chakraborty, Philip W. Kantoff, Subhiksha Nandakumar et al.|Clinical Cancer Research|2022Cited by 51
Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate TumorsGoutam Chakraborty, Philip W. Kantoff, Nabeela Khan Patail et al.|Clinical Cancer Research|2020Cited by 21
Increased <scp> <i>MYBL2</i> </scp> expression in aggressive hormone‐sensitive prostate cancerYuki Yoshikawa, Christopher J. Sweeney, Konrad H. Stopsack et al.|Molecular Oncology|2022Cited by 17